Harmony Biosciences (HRMY) Stock Price, News & Analysis

Company Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Key Stats

• Today's Range: $33.48 to $34.49
• 50-Day Range: $27.94 to $35.91
• 52-Week Range: $26.47 to $41.61
• Volume: 942,573 shs
• Average Volume: 606,376 shs
• Market Capitalization: $1.96 billion
• P/E Ratio: 16.14
• Dividend Yield: N/A
• Price Target: $52.78
• Consensus Rating: Buy

Harmony Biosciences Stock Analysis - MarketRank™

Harmony Biosciences scored higher than 99% of companies evaluated by MarketBeat, and ranked 14th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Harmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Harmony Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 27.98%

Earnings Growth

Earnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Harmony Biosciences is 16.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.32.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harmony Biosciences is 16.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.99.

Price to Earnings Growth Ratio

Harmony Biosciences has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Harmony Biosciences has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.85% of the float of Harmony Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Harmony Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harmony Biosciences has recently decreased by 21.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harmony Biosciences does not currently pay a dividend.

Dividend Growth

Harmony Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.85% of the float of Harmony Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Harmony Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harmony Biosciences has recently decreased by 21.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 1.74

News Sentiment

Harmony Biosciences has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Harmony Biosciences this week, compared to 6 articles on an average week.

Search Interest

6 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

5 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HRMY Stock Analysis - Frequently Asked Questions

How have HRMY shares performed this year?

Harmony Biosciences' stock was trading at $34.41 on January 1st, 2025. Since then, HRMY stock has decreased by 1.0% and is now trading at $34.05.
View the best growth stocks for 2025 here.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its quarterly earnings results on Tuesday, May, 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.19. The company's revenue for the quarter was up 19.5% on a year-over-year basis.
Read the conference call transcript.

When did Harmony Biosciences IPO?

Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Who are Harmony Biosciences' major shareholders?

Harmony Biosciences' top institutional investors include Vanguard Group Inc. (8.18%), American Century Companies Inc. (2.24%), LSV Asset Management (2.08%) and Massachusetts Financial Services Co. MA (1.31%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Sandip Kapadia, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks.
View institutional ownership trends.

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/29/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HRMY
• CIK: 1802665
• Web: www.harmonybiosciences.com
• Phone: 484-539-9800
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $52.78
• High Stock Price Target: $70.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +55.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.62
• Trailing P/E Ratio: 16.14
• Forward P/E Ratio: 14.01
• P/E Growth: 0.47
• Net Income: $128.85 million
• Net Margins: 17.98%
• Pretax Margin: 25.71%
• Return on Equity: 23.16%
• Return on Assets: 14.24%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 3.24
• Quick Ratio: 3.20

Sales & Book Value

• Annual Sales: $744.85 million
• Price / Sales: 2.63
• Cash Flow: $2.54 per share
• Price / Cash Flow: 13.38
• Book Value: $7.97 per share
• Price / Book: 4.27

Miscellaneous

• Outstanding Shares: 57,424,000
• Free Float: 39,465,000
• Market Cap: $1.96 billion
• Optionable: Optionable
• Beta: 0.82